VIVUS Inc. announced the addition of three executives to the Company's senior leadership team. John Amos has joined as the company's new Chief Executive Officer and a new member of the company's Board of Directors. Scott Oehrlein is Chief Operations Officer, a newly created position within the Company.

Kenneth Suh will continue as President and Chief Executive Officer of Willow Biopharma Inc., now a wholly-owned subsidiary of VIVUS. All three executives were previously members of the senior leadership team at Willow Biopharma Inc. in Toronto, Canada. John Amos served as the Executive Chairman of Willow Biopharma Inc. from May 2017 to April 2018.

Previously, he served as the Chief Executive Officer of ORIX Healthcare Capital LLC from October 2012 to April 2017. Mr. Amos served as the Operating Partner and Portfolio Company Board Member of BioVeda China Fund from February 2008 to October 2012. He served as the Chief Executive Officer and President of the Oncology Therapeutics Network from June 2005 to November 2007 and was a special advisor to McKesson Corporation from November 2007 to May 2008.

Mr. Amos served as the President of the Oncology Therapeutics Network of Bristol Myers Squibb,from June 2003 through May 2005. Mr. Amos has previously served on the board of directors of TD2, Navigating Cancer, CITIC Pharmaceuticals, Aesyntix Health, Prodigy Health, Apollo Health Street, Quinian Health, Oncology Therapeutics Network, Oncology Molecular Imaging and Matawan Pharmaceuticals. Kenneth Suh founded Willow Biopharma Inc. in August 2015.

With the VIVUS transaction, he will continue to serve as President, Chief Executive Officer and Director of Willow Biopharma Inc. Previously he founded KRIM Biopharma Inc. in 2013 and served as President and Chief Executive Officer and Director from August 2013 to August 2015. Scott Oehrlein served as the Global Chief Operations Officer of Willow Biopharma Inc. from November 2017 to April 2018. Previously he served as Vice President and Head of General Medicines Sales/Diabetes and CV Sales, U.S. Sanofi from April 2014 to June 2017.